--- title: "Jazz Pharmaceuticals extends term loan to 2033" url: "https://aibio.space/news/jazz-pharmaceuticals-extends-term-loan-2033-adds-273-310-355-18/" publisher: "aibio.space (Biotech Investor Relations News)" date: "2026-09-23" section: "Debt Financing" tickers: "NASDAQ:JAZZ" source: "https://www.sec.gov/Archives/edgar/data/1232524/000119312526399425/d163027d8k.htm" summary: "Bank of America, N.A. is administrative agent. The maturity of the dollar term loans moves from May 5, 2028 to May 5, 2033, and year-end 2025 cash fell to" --- By the aibio.space news desk. Sources - [Jazz Pharmaceuticals plc 8-K (2026-09-23)](https://www.sec.gov/Archives/edgar/data/1232524/000119312526399425/d163027d8k.htm) - [Jazz Pharmaceuticals plc 10-K (2026-02-24): business](https://www.sec.gov/Archives/edgar/data/1232524/000123252426000013/jazz-20251231.htm) - [Jazz Pharmaceuticals plc financial data (SEC XBRL)](https://www.sec.gov/Archives/edgar/data/1232524/000123252426000013/) [JAZZ](https://aibio.space/companies/jazz-pharmaceuticals/) 2026-09-23 # Jazz Pharmaceuticals extends term loan to 2033, adds $273,310,355.18 Tickers [JAZZ](https://aibio.space/companies/jazz-pharmaceuticals/) Bank of America, N.A. is administrative agent. The maturity of the dollar term loans moves from May 5, 2028 to May 5, 2033, and year-end 2025 cash fell to $1.39 billion from $2.41 billion a year earlier. ## Key facts - **Company**: Jazz Pharmaceuticals plc (NASDAQ: JAZZ) - **News type**: Debt Financing - **Primary source**: [Jazz Pharmaceuticals plc 8-K (2026-09-23)](https://www.sec.gov/Archives/edgar/data/1232524/000119312526399425/d163027d8k.htm) *Stock prices on an electronic board. CC0, via rawpixel. The picture shows the field, not the companies named.* ## The amendment and the new tranche Jazz Pharmaceuticals plc said its wholly owned subsidiary, Jazz Financing Lux S.à r.l., signed Amendment No. 4 to its credit agreement on September 23, 2026. The amendment extends the maturity and reprices the Tranche B-2 dollar term loans, which were incurred on July 19, 2024. Some existing lenders converted their Tranche B-2 loans into a new class, Tranche B-3 dollar term loans. Jazz Lux also borrowed $273,310,355.18 of additional B-3 loans. The proceeds repaid the B-2 loans that were not converted. The filing gives the principal of the B-2 loans before the amendment and of the B-3 loans after it as $1,895,000,000 for each. The margin on the B-3 loans is 1.75% for Term SOFR borrowings and 0.75% for prime rate borrowings, a decrease of 50 basis points. The loans have a Term SOFR floor of 0.50%, and no credit spread adjustment applies. They amortize in quarterly installments of 0.25% of the initial principal, with the remaining balance due May 5, 2033. The filing says the B-3 loans have substantially the same material terms as the earlier dollar term loans, including prepayment, security, covenants and events of default. Those earlier loans are the initial dollar term loans of May 5, 2021, the Tranche B-1 loans of January 19, 2024, and the B-2 loans of July 19, 2024. ## Lenders, agents and advisers Bank of America, N.A. is administrative agent under the credit agreement dated May 5, 2021, as amended by the LIBOR Successor Rate Conforming Changes Amendment of June 7, 2023, Amendment No. 1 of January 19, 2024, Amendment No. 2 of July 19, 2024 and Amendment No. 3 of November 26, 2024. U.S. Bank Trust Company, National Association is collateral trustee. The 8-K's exhibit list names U.S. Bank Trust Company as successor in interest to U.S. Bank National Association. The filing does not name the lenders that converted their loans, and it names no placement agent, financial advisor or company counsel. The Irish parent and other subsidiaries are parties as borrowers or guarantors, and the 8-K does not name the other subsidiaries. ## What Jazz is Jazz Pharmaceuticals plc describes itself as a global biopharmaceutical company focused on rare diseases, often with limited or no therapeutic options. Its lead products are Xywav, approved for narcolepsy and idiopathic hypersomnia, Epidiolex for seizures associated with LGS, DS or TSC, and Ziihera, approved under the accelerated approval pathway for previously treated HER2-positive biliary tract cancer. The 10-K also lists Modeyso, approved in August 2025 for diffuse midline glioma, Zepzelca for small cell lung cancer, and Rylaze for acute lymphoblastic leukemia. The company says its strategy rests on commercial execution, its pipeline and "effectively deploying capital" through corporate development. The 8-K says the new B-3 loans repaid the B-2 loans that were not converted and states no other use. ## The money The 10-K shows a net loss of $356.1 million for 2025, after net income of $560.1 million for 2024. Cash provided by operations was $1.36 billion in 2025 and $1.40 billion in 2024. Year-end cash and cash equivalents were $1.39 billion for 2025, according to a 10-Q filed August 3, 2026. They were $2.41 billion for 2024. At June 30, 2026, cash and cash equivalents were $1.62 billion. The repricing lowers the margin and pushes the principal out five years. The B-3 principal stands at $1,895,000,000, and the company's cash position fell sharply during 2025. The repricing lowers the rate on that debt but does not reduce the principal. ## What comes next The next fixed date is May 5, 2033, when the B-3 balance falls due, subject to quarterly amortization before then. The 8-K gives no timetable for further steps on the loan and no plan for the $273,310,355.18 of new B-3 loans beyond repaying the B-2 loans that were not converted. [Report an error](https://aibio.space/reputation/#correction) ## Companies in this story JAZZ Jazz Pharmaceuticals plc NASDAQ · Ireland Open the desk ## More in Debt Financing Debt Financing ### [Pelthos amends Horizon venture loan, funds Loans E to H and adds Loans I and J](https://aibio.space/news/pelthos-amends-horizon-venture-loan-funds-loans-e-h-adds-loans/) Oct 30, 2026 Debt Financing ### [Repligen announces $1.0 billion private convertible notes transaction](https://aibio.space/news/repligen-announces-1-0-billion-private-convertible-notes-transaction/) Oct 30, 2026 Debt Financing ### [FOXO to buy Ludwig Enterprises preferred stock with majority voting power](https://aibio.space/news/foxo-buy-ludwig-enterprises-preferred-stock-majority-voting-power/) Oct 29, 2026 --- Source page: https://aibio.space/news/jazz-pharmaceuticals-extends-term-loan-2033-adds-273-310-355-18/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Jazz Pharmaceuticals extends term loan to 2033", 2026-09-23, https://aibio.space/news/jazz-pharmaceuticals-extends-term-loan-2033-adds-273-310-355-18/